+100%-
Ramsay Awards

The Ramsay Awards provide pilot grants for ME/CFS and long-COVID researchers.

The Ramsay Awards provide pilot grants that give researchers the ability to gather the data they need to apply for much larger NIH grants. As it has over the past couple of years, the Solve ME Initiative places a heavy focus on funding clinical trials that could quickly help people with ME/CFS.

I asked Solve M.E. if they were seeing increased interest in the Ramsay Awards since long COVID appeared on the scene. Overall, they were. The fifteen applications this year were less than they received last year but more than in the pre-pandemic period and the quality of the applications – as measured by the grant reviewer scores – is higher than before, as well.

I asked how two of the five grants ended up being for long COVID? They replied that they asked for proposals that could advance chronic fatigue syndrome (ME/CFS) and for long-COVID research that could be applied to ME/CFS. The studies that received the best scores were given funding. They asserted that:

“By being able to study individuals who were infected with SARS-CoV-2 at an early stage of disease, we will inevitably strengthen our understanding of the pathways involved in those with ME/CFS and vice versa.”

The Poop-Plus Study

Immunosenescence and Premature Aging of the Immune System in ME/CFS

Katherine-Seton-2

Katherine Seton has ME/CFS and did her Ph.D. on ME/CFS

I don’t know if any clinical trials are more needed than fecal microbiota transplant (FMT) trials that have the potential to safely reset ME/CFS patients’ microbiome, thus reducing leaky gut and inflammation, and possibly even improving one’s ability to exercise.

If I read it right, Katherine Seton’s Ramsay award is piggybacking on the 80-person Norwegian Comeback fecal transplant trial. The study will determine what effect the fecal transplants are having, biologically, as they assess immune functioning and premature immune system aging (immunosenescence). That makes sense given the findings of T-cell and NK cell exhaustion. I’m hoping the fact that Dr. Seton is doing this study means that the Comeback team feels the fecal transplants are having a positive effect.

Dr. Seton has quite a story of her own. A person with ME/CFS, her Ph.D. was on ME/CFS (“Investigating immune reactivity to the intestinal microbiome in ME/CFS”). She went above and beyond most studies by choosing to enroll people with severe ME/CFS in her study.

Like This Blog?

Make Sure You Don't Miss Another One!

Register for our free ME/CFS, fibromyalgia, and long COVID blogs here.

The Gist

  • Solve M.E.’s Ramsay Grant Awards provide funding to researchers to produce the data they need for much bigger grants to focus, once again, on new treatment possibilities. 
  • Katherine Seton’s award will allow her to determine the biological effects – with a special focus on immune functioning – fecal transplants are having on people with ME/CFS. 
  • The stellate ganglion block award will determine if temporarily blocking a key throughway for sympathetic nervous system signals will reset the autonomic nervous system, thus reducing fight/flight, improving blood flows, reducing pain, and perhaps even improving mitochondrial functioning in ME/CFS. 
  • The enhanced external counterpulsation (EECP) award will determine if a device that can be used at home will increase blood flows and reduce symptoms in long COVID. 
  • Rob Wust will compare muscle biopsies before and after exercise to investigate how exercise produces PEM, including the role microclots may play. 
  • Avik Roy of Simmaron will suppress an autophagy gene in mice to see if doing so will produce PEM in them. If successful, that will buttress a potential link between impaired autophagy, inhibited mitochondrial activity, reduced oxygen consumption, and potentially open new treatment possibilities.

Just as she was recovering from her longest and most severe #mecfs relapse in July, she came down with COVID – a worrying development as her body has a 14-year history of failing to recover fully following infections. She plans to stay in academia and pursue a postdoctoral position in ME/CFS research and have her own ME/CFS research group one day.

(According to the timeline, the Norwegian fecal transplant study is not expected to end until 2026 (!). That’s when, if the timeline is correct, the last participant is expected to get a fecal transplant. Add data analysis, writeup, and publication, and we’re probably looking at a 9-year trial and a 2028 publication. (It started in 2019). Let’s hope that the timeline is not correct.)

(Producing quick, rigorously produced clinical trials are one place the RECOVER Initiative (for long COVID), with its massive infrastructure, funding, and ready patient populations, should shine. I wouldn’t be surprised to see a fecal transplant trial in the first round of RECOVER clinical trials.)

Autonomic Nervous System Reset?

The Effect of Stellate Ganglion Block on ME/CFS Symptoms and Plasma Metabolites

Talk about another timely study. With all the focus placed on the autonomic nervous system and, in particular, the sympathetic nervous system, it seems surprising that the stellate ganglion block, (SGB) technique – which has been used for years in other diseases and appears to be quite safe – somehow didn’t get on the ME/CFS communities’ radar screen until the last year or so.

The procedure seems relatively simple: inject anesthesia near the stellate ganglia to block the sympathetic nervous system signals emanating from the brainstem and reset the fight/flight system to improve immune functioning, blood flows, orthostatic intolerance (ability to stand), gut functioning – even possibly mitochondrial functioning. That’s quite a package!

Duricka Headshot

Dr. Duricka is a neuroscientist with a broad background in academic and industry research.

SGB is another potential gift to ME/CFS from long COVID. It popped up on our radar screens after a case series of its effects on long COVID was published in a scientific journal. The recoveries cited were pretty dramatic, putting SGB high on the list of potential treatments to try.

Bye-Bye Fight or Flight? Hello Better Blood Flows? Stellate Ganglion Blocks, Long COVID, and ME/CFS/FM/POTS

The study will assess the effects of SGB on orthostatic tolerance, cognitive functioning, symptoms, and plasma metabolites in ME/CFS.

Bye-Bye Fight or Flight? Hello Better Blood Flows? Stellate Ganglion Blocks, Long COVID, and ME/CFS/FM/POTS

The Squeezer: Improving Blood Flows

Enhanced External Counterpulsation (EECP) to Treat Long Covid Fatigue – A Randomized Controlled Trial

Who is not for increasing blood flows? Given the reduced blood flows in the brain, the low blood volume, the blood pooling in the legs, and the possible problems with the microcirculation, it would be surprising, indeed, if no problems with blood flows existed in ME/CFS and long COVID.

Enter enhanced external counter-pulsation (EECP) – a non-invasive outpatient therapy (you can do it in your home) that has been shown to “improve the functional status and quality of life in some people with impaired blood flows and other blood vessel problems.”

Again, it seems surprising that EECP has not been assessed in either ME/CFS or postural orthostatic tachycardia syndrome (POTS). It may be because it’s often used in people with heart problems that don’t exist in ME/CFS. EECP, though, increases blood flows back to your heart, and a reduction in blood flows to the heart (preload failure) is present in a significant subset of ME/CFS patients.

Systrom’s Keynote Address Kicks off IACFS/ME ME/CFS and Long-COVID Conference

Several case reports have suggested that EECP may help people with long COVID-induced POTS. One person’s brain fog lifted, her shortness of breath improved, and she ultimately returned to health. Another person showed moderate improvements.

If positive, this study could open up new treatment possibilities for both ME/CFS and POTS. This study, though, is focused on long COVID. It will assess functional status, markers of blood vessel health, and quality of life.

A Deep Dive into Post-Exertional Malaise

Skeletal Muscle Pain and Post-Exertional Malaise in Patients with Long Covid: from Pathophysiology to Treatment

“we will provide a better fundamental understanding of the biological aspects of skeletal muscle adaptations during PEM”

Skeletal muscle fibromyalgia

Skeletal muscles – it took a muscle biopsy to uncover carnitine fatty-acid metabolism problems in one study. Carnitine levels in the plasma did not.

This study is beyond overdue. Studies that assess muscle biopsies before and after exercise are pretty rare – if they exist at all. Add in a look at the role microclots may be playing and you’ve got a potentially quite impactful study.

As with blood flows, it would be crazy to think the muscles are not affected in ME/CFS. One review, “Old muscle in young body”, suggested the muscles in ME/CFS were aging more rapidly than normal. The mitochondrial problems revealed by muscle biopsies enabled Systrom’s $8 million mitochondrial trial to take place. Studies suggest that slow-twitch muscle fibers may be being exchanged for fast-twitch ones in both long COVID and ME/CFS. Plus, fibromyalgia muscle studies regularly show problems.

It’s good to see this researcher, in particular, get involved in long COVID (and hopefully ME/CFS). A Dutch researcher, Rob Wust, has a long track record and has already found muscle fibre atrophy, metabolic alterations, and immune cell infiltration in the muscles of people with long COVID.

Long-COVID Exercise Study Points to Mitochondrial Dysfunction and Twitchy Muscles

Having recently co-authored a paper on “Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle“, he also appears to be an expert in a mitochondrial problem (long chain fatty acids and carnitine) that’s captured a lot of attention in ME/CFS lately.

Even in the abstract of his long-COVID muscle fiber study – where space is limited and authors must choose their words wisely – he included ME/CFS in stating: “a deeper molecular understanding of skeletal muscle adaptations in patients with long-covid, and ultimately also patients with ME/CFS.”

A Different Mitochondrial Issue in ME/CFS Emerges

Targeting Atg13 in ME/CFS

Ramsay 2022_roy_headshot 2

With Avik Roy Ph.D. , a neuroscientist, and Gunnar Gottschalk, Ph.D. have reinvigorated Simmaron’s research efforts.

The last study from the Simmaron Research Foundation’s Avik Roy Ph.D. is pure ME/CFS and demonstrates how, in some cases, ME/CFS researchers have sprinted ahead of the long-COVID field. It’s the first to assess something called autophagy in both fields. Plus, it’s attempting to create an ME/CFS animal model.

Autophagy doesn’t sound that important – it simply clears out unused proteins and old and damaged mitochondria from the cells, but impaired autophagy results in reduced oxygen consumption, mitochondrial activity, and even problems with exercise. It can also turn cells into pro-inflammatory generators, and lead to clumps of proteins that can damage all sorts of processes.

SImmaron’s work has found indications of reduced autophagy in ME/CFS. This Ramsay study will attempt to duplicate the PEM we see in ME/CFS by altering a specific autophagy gene in mice. A successful result will strengthen the potential link between autophagy, mitochondrial problems, and PEM in ME/CFS and lead to further studies. It would also provide different treatment possibilities than we’ve seen thus far. It’s another example of the Ramsay Awards funding a new and much-needed look at ME/CFS.

As an added bonus, the awards support the work of the home-grown ME/CFS research team at Simmaron that emerged after Gunnar Gottschalk received his Ph.D. and Avik Roy Ph.D. joined the team. Seeing this group engage in novel approaches to ME/CFS is not surprising. The studies principal investigator, Avik Roy, won the Rapid Response Innovation award in Parkinson’s disease from the MJFox foundation, the John E Trufant award for excellence in research by Rush University, and the YIEE award by the American society for neurochemistry. He’s also received multiple patents for his novel nasal drug (KeptideTM) for COVID-19.

Cleaning Crisis? Defective Mitochondrial Cleanup In ME/CFS May Be Impairing Energy Production

Conclusion

Particularly in an underfunded field like chronic fatigue syndrome (ME/CFS) seed grants like the Ramsay Awards play an important role by paving the way for big studies. Thus far, the Ramsay Awards have brought in over $8 million to the ME/CFS research field.

GET FREE ME/CFS AND FIBROMYALGIA INFO

Like the blog you're reading? Don't miss another one.

Get the most in-depth information available on the latest ME/CFS and FM treatment and research findings by registering for Health Rising's free  ME/CFS and Fibromyalgia blog here.

Pin It on Pinterest

Shares
Share This